Eisai Inkomsten in het verleden

Verleden criteriumcontroles 1/6

De winst van Eisai is gedaald met een gemiddeld jaarlijks percentage van -23%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 4.3%. De inkomsten zijn groeide met een gemiddeld percentage van 2.7% per jaar. Het rendement op het eigen vermogen Eisai bedraagt 5.1% en de nettomarge bedraagt 5.4%.

Belangrijke informatie

-23.0%

Groei van de winst

-23.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	3.4%
Inkomstengroei	2.7%
Rendement op eigen vermogen	5.1%
Nettomarge	5.4%
Volgende winstupdate	07 Feb 2025

Recente prestatie-updates uit het verleden

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Nov 15

Recent updates

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Nov 21

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Nov 15

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Opbrengsten en kosten

Hoe Eisai geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSE:4523 Opbrengsten, kosten en inkomsten (JPY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	753,221	40,970	382,177	168,009
30 Jun 24	733,845	32,648	387,882	169,347
31 Mar 24	741,751	42,406	364,084	169,021
31 Dec 23	749,460	45,421	346,208	176,070
30 Sep 23	759,329	48,096	346,619	174,257
30 Jun 23	757,075	48,874	341,916	175,647
31 Mar 23	744,402	55,432	348,139	172,999
31 Dec 22	737,098	26,705	373,875	169,848
30 Sep 22	752,500	32,233	382,752	173,324
30 Jun 22	741,594	32,690	374,428	168,422
31 Mar 22	756,226	47,954	356,847	171,738
31 Dec 21	712,935	57,311	317,150	165,418
30 Sep 21	691,250	62,508	293,153	162,699
30 Jun 21	679,253	59,855	282,369	161,584
31 Mar 21	645,942	42,119	272,568	150,299
31 Dec 20	707,888	93,682	271,476	145,248
30 Sep 20	713,400	120,571	261,973	139,628
30 Jun 20	707,203	124,523	253,516	141,217
31 Mar 20	695,621	121,767	248,554	140,116
31 Dec 19	661,646	96,659	244,091	146,367
30 Sep 19	631,974	57,725	239,503	147,863
30 Jun 19	643,531	72,747	233,180	140,143
31 Mar 19	642,834	63,386	223,798	144,844
31 Dec 18	627,367	63,714	212,469	139,100
30 Sep 18	625,106	65,679	195,229	138,461
30 Jun 18	611,499	54,347	186,198	140,514
31 Mar 18	600,054	51,845	179,915	139,579
31 Dec 17	569,814	29,048	178,312	134,955
30 Sep 17	554,276	30,269	178,090	123,639
30 Jun 17	544,027	29,425	176,249	119,503
31 Mar 17	539,097	39,358	175,633	112,478
31 Dec 16	530,696	55,031	175,240	110,471
30 Sep 16	542,313	71,812	178,825	114,420
30 Jun 16	545,602	69,227	182,036	115,750
31 Mar 16	547,922	54,933	188,227	122,307
31 Dec 15	566,435	44,886	192,375	125,396
30 Sep 15	554,912	43,871	191,627	132,652
30 Jun 15	554,885	43,021	192,617	135,534
31 Mar 15	548,465	43,254	189,910	131,907
31 Dec 14	560,795	40,152	90,324	228,412
30 Sep 14	561,938	15,717	126,410	192,643
30 Jun 14	578,945	29,225	163,903	159,644
31 Mar 14	600,363	32,955	210,544	130,544
31 Dec 13	590,152	43,756	223,092	120,377

Kwaliteitswinsten: 4523 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (5.4%) 4523 } zijn lager dan vorig jaar (6.3%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 4523 is de afgelopen 5 jaar met 23% per jaar gedaald.

Versnelling van de groei: De winstgroei 4523 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: 4523 had het afgelopen jaar een negatieve winstgroei ( -14.8% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 12.2% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 5.1% ) van 4523 wordt als laag beschouwd.

Eisai Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

First half dividend of JP¥80.00 announced

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Is Eisai (TSE:4523) Using Too Much Debt?

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody